Yesterday, the Supreme Court made a momentous decision that will start to untangle the genetic patent mess. It ruled unanimously that the BRCA1 and BRCA2 genes could not be patented, because they are a product of nature. I have always thought it obvious and never could understand how they ever received a patent.
Whereas the patent holder, Myriad was charging $4000, which may not have been reimbursed by insurance companies. A sister company of FTDNA, DNATraits, immediately offered the test for $995.